Medicaid GLP-1 Obesity Coverage Cuts Erased 84.7% of Dispensing, Study Finds
A quasi-experimental study published in Cureus on November 6, 2026, reports that when five state Medicaid programs withdrew coverage of GLP-1 receptor agonists for obesity in late 2025 and January 2026, reimbursed dispensing of obesity-indicated GLP-1 drugs fell 84.7% relative to states that kept coverage. The analysis, covering 50 states and the District of Columbia from 2021 through the first quarter of 2026, is the first multi-state measurement of what happens to GLP-1 peptide dispensing when public payers stop reimbursing weight-management indications.
For the peptide therapy and research peptide industry, the finding matters because it quantifies how quickly demand for GLP-1 peptides can contract when a single payer changes a coverage rule. Clinics, telehealth operators, compounding pharmacies and API suppliers that built capacity around obesity-indicated GLP-1 demand now have a documented example of how fast that volume can disappear — and how little of it shifts to older antiobesity medicines.
What the study actually measured
The authors used quarterly Medicaid State Drug Utilization Data (SDUD) and compared dispensing in five states that withdrew obesity coverage against 12 states that continued it, applying difference-in-differences and event-study models. Each state’s diabetes-indicated GLP-1 dispensing served as a within-state comparison series, a design choice intended to separate coverage effects from broader market trends.
The five withdrawing states were not marginal players. According to the study, they accounted for 2,428,709 (65.2%) of 3,725,732 obesity-indicated GLP-1 RA prescriptions reimbursed by Medicaid in 2025, meaning the policy change touched roughly two-thirds of the program’s obesity-indicated GLP-1 volume.
Two important limitations are stated by the authors. The data count reimbursed prescriptions, not individual patients, so the study measures changes in reimbursed dispensing rather than confirmed treatment discontinuation among individual enrollees. Cells with fewer than 11 prescriptions are suppressed in the source data and were counted as zero, and the most recent quarter (Q1 2026) is marked provisional because of reporting lag.
Key numbers: the size and speed of the decline
The headline estimate is a 29.1 fewer prescriptions per 1,000 enrollees per quarter in withdrawing states (95% CI: 14.3–43.9), alongside the 84.7% relative decline (95% CI: 64.5%–93.4%; exact permutation p < 0.001). Pre-announcement differences between the two groups were small and not statistically significant, which the authors present as support for the parallel-trends assumption.
The speed is notable. In the first quarter without coverage, obesity-indicated dispensing fell by 61% to 96% across individual withdrawing states. The four states that withdrew on January 1, 2026 reimbursed 661,353 obesity-indicated prescriptions in the preceding quarter and 134,647 in the next — a decline of 526,706, or 79.6%.
| Measure | Result | Source |
|---|---|---|
| Obesity-indicated GLP-1 RA dispensing, withdrawing vs. continuing states | −84.7% (95% CI: 64.5%–93.4%; p < 0.001) | Cureus study, SDUD 2021–Q1 2026 |
| Absolute change | 29.1 fewer prescriptions per 1,000 enrollees per quarter (95% CI: 14.3–43.9) | Same |
| Diabetes-indicated GLP-1 RA dispensing | −3.2% (95% CI: −23.4% to 22.2%), not significant | Same |
| Four states withdrawing Jan 1, 2026 | 661,353 → 134,647 prescriptions; −526,706 (−79.6%) | Same |
| Older antiobesity medication substitution | Increase of at most 2.9 prescriptions per 1,000 enrollees | Same |
| Withdrawing states’ share of 2025 obesity-indicated Medicaid GLP-1 prescriptions | 2,428,709 of 3,725,732 (65.2%) | Same |
| State Medicaid programs covering GLP-1 RAs for obesity, October 2025 | 16 of 51 (31.4%) | KFF counts, as cited |
Why it matters for peptide therapy and research peptide markets
The substitution finding is the most consequential for suppliers. Dispensing of older antiobesity medications rose by at most 2.9 prescriptions per 1,000 enrollees after withdrawal — a fraction of the 29.1-prescription decline. In practical terms, the data suggest that when Medicaid stopped paying for obesity-indicated GLP-1 RAs, most of that reimbursed volume did not move to another covered weight-management drug class inside Medicaid.
Industry observers note that this does not establish where the volume went. Patients may have paid out of pocket, shifted to commercial insurance, entered cash-pay telehealth programs, or stopped treatment altogether; the SDUD dataset captures only Medicaid-reimbursed dispensing. For clinics and telehealth platforms, that ambiguity is itself the business question: a coverage withdrawal can convert insured demand into either self-pay demand or no demand, and the study cannot distinguish between the two.
The diabetes-indicated series showed no significant change (−3.2%; 95% CI: −23.4% to 22.2%), consistent with the Medicaid Drug Rebate Program’s requirement that states cover nearly all approved outpatient drugs, with weight-loss drugs among the few classes states may exclude. The wide confidence interval, however, means moderate changes in diabetes-indicated dispensing cannot be ruled out.
For research-peptide suppliers and buyers, the episode is a reminder that GLP-1 demand is policy-sensitive at the payer level, not only at the consumer level. A research peptide is supplied for a defined scientific or laboratory purpose, and a research-use designation does not establish sterility, safety or authorization for human administration; approved GLP-1 medicines such as semaglutide (Wegovy, approved for chronic weight management in June 2021) and tirzepatide (Zepbound, approved in November 2023) remain prescription products whose use requires medical supervision. Supply planning that treats all GLP-1-adjacent demand as one undifferentiated pool will misread a market where reimbursement rules can remove most of a channel within one quarter.
Budget pressure, state by state
The authors attribute the withdrawals to budget pressure. California ended coverage under its enacted 2025–2026 state budget to reduce pharmacy spending, effective January 1, 2026, according to a Medi-Cal Rx notice dated October 21, 2025. North Carolina suspended coverage for 10 weeks beginning October 2025 because of a state funding shortfall and reinstated it on December 12, 2025. Massachusetts and Michigan took a different route, tightening clinical criteria rather than ending coverage outright; narrower criteria in two states were followed by declines of 23% to 37%.
The coverage base was already narrow. By October 2025, 16 of 51 state Medicaid programs (31.4%) covered GLP-1 RAs for obesity, according to KFF counts cited in the study, even though 40% of adult Medicaid enrollees had obesity in 2021. Prior analyses comparing covering and noncovering states between 2022 and 2024 found higher use where the drugs were covered, but use below 5% of eligible beneficiaries even in covering states, plus wide variation in prior authorization criteria.
This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com. PeptideDDP is a valuable source of frontline industry intelligence; readers tracking payer-driven shifts in peptide demand can visit PeptideDDP.com for the latest first-hand information and industry updates.
What comes next for clinics, suppliers and researchers
The authors state that protecting enrollees already receiving these drugs — for example, by honoring existing authorizations — might limit treatment interruption, but this has not been evaluated. That is an explicit research gap, not a demonstrated policy effect, and it is the single most useful question for clinic operators modeling continuity of care.
Several data questions remain open. Because SDUD counts prescriptions rather than patients, the study cannot say how many individuals stopped therapy versus switched payment channels. The provisional Q1 2026 quarter may be revised. And the authors note that withdrawal savings come largely from ending reimbursement for people already in treatment, who often regain weight when these drugs are stopped — a point drawn from prior literature rather than measured in this dataset.
For the peptide supply chain, the practical watch items are payer rule changes in the remaining covering states, the share of lost Medicaid volume that reappears as cash-pay or compounded demand, and whether narrower prior-authorization criteria produce the 23%–37% declines seen in the two restricting states. Suppliers evaluating GLP-1-adjacent capacity should treat reimbursement policy as a demand variable with quarterly resolution, not a background assumption.
FAQ
How much did GLP-1 obesity dispensing fall after Medicaid coverage withdrawal?
Reimbursed obesity-indicated GLP-1 RA dispensing fell 84.7% in withdrawing states relative to continuing states (95% CI: 64.5%–93.4%), equivalent to 29.1 fewer prescriptions per 1,000 enrollees per quarter, according to the Cureus study.
Did patients switch to older weight-loss drugs?
Only marginally within Medicaid data: dispensing of older antiobesity medications increased by at most 2.9 prescriptions per 1,000 enrollees, far below the 29.1-prescription decline in GLP-1 dispensing.
Did diabetes-indicated GLP-1 use change?
No significant change was detected (−3.2%; 95% CI: −23.4% to 22.2%), consistent with Medicaid rebate rules that generally require coverage of approved outpatient drugs for diabetes.
Does the study prove individual patients stopped treatment?
No. The data count reimbursed prescriptions, not patients, so the study measures changes in reimbursed dispensing, not confirmed discontinuation among individual enrollees.